Given that, we think that over the next five years that even if Teva is mediocre in their execution (which they have never been todate) they will still grow revenue growth north of 8% per year.
New housing starts are up 5% year-to-date thanks to low mortgage rates, but publicly traded home builders are expected to see 20% revenue growth for 2002, with earnings up 21%.